A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study

详细信息    查看全文

• 作者：Carolyn K. McCourt ; MD^a ; ^{mccourtc@wudosis.wustl.edu} ; Wei Deng ; PhD^b ; ^{wdeng@gogstats.org} ; Don S. Dizon ; MD^c ; ^{ddizon@mgh.harvard.edu} ; Heather A. Lankes ; PhD MPH^b ; ^{hlankes@gogstats.org} ; Michael J. Birrer ; MD PhD^c ; ^{mbirrer@partners.org} ; Michele M. Lomme ; MD^d ; ^{mlomme@wihri.org} ; Matthew A. Powell ; MD^e ; ^{mpowell@wustl.edu} ; James E. Kendrick ; MD^f ; ^{tkendrick2@gmail.com} ; Joel N. Saltzman ; MD^g ; ^{Joel.Saltzman@uhhospitals.org} ; David Warshal ; MD^h ; ^{warshal-david@cooperhealth.edu} ; Meaghan E. Tenney ; MDⁱ ; ^{meaghan.tenney@northside.com} ; David M. Kushner ; MD^j ; ^{dmkushner@wisc.edu} ; Carol Aghajanian ; MD^k ; ^{aghajanc@mskcc.org}
• 关键词：Ixabepilone ; Carcinosarcoma
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：101-106
• 全文大小：516 K
• 卷排序：144

文摘

Prospective Phase II trial of ixabepilone in recurrent or persistent uterine carcinosarcoma The objective response rate of nearly 12% did not meet the predefined criteria for clinical activity. Median progression free survival was 1.7 months and median overall survival was 7.7 months.